Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

NESN.SIX

Nestlé

Consumer Defensive | Packaged Foods

Global food and beverage company known for brands like Nescafé, KitKat, Gerber, and Purina with operations in 186 countries.

Flagship Insight

How Metabolic Innovation Is Quietly Restructuring The Global Food Supply Chain

Analysis reveals sharp divergence regarding long-term volume growth as metabolic innovations alter consumer demand. While high consensus exists on robust cash generation and defensive restructuring benefits, opinions clash on whether agricultural supply-chain inflation and shifting consumer biology represent a temporary cyclical headwind or a permanent structural impairment to legacy brand moats.

Forecast TimelineUpdated On Jul 03 2026

Nestlé (NESN) Stock Forecast and AI Rating

Recommendation

No Action - Keep Monitoring

Only one horizon is positive; wait for broader confirmation.

2027

1-Year

BUY

92 CHF

+8.7%

+10.5% IF INCL. DIVS

2029

3-Year

N/A

105 CHF

+24%

2031

5-Year

NEUTRAL

116 CHF

+37%

+52% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The asset is navigating a complex structural transition characterized by a shifting metabolic paradigm and persistent macroeconomic headwinds. While legacy volume growth faces pressure from pharmacological appetite suppressants and elevated supply-chain entropy, aggressive corporate restructuring and non-core divestitures are designed to defend operating margins. Robust free cash flow generation and a high dividend yield establish a strong valuation floor, though the higher-for-longer interest rate regime continues to compress the historical valuation premium. Sophisticated investors must weigh the near-term margin expansion driven by cost-out initiatives against the long-term risk of terminal volume compression in legacy categories.

Key insights

Restructuring initiatives, including a six percent global headcount reduction, aim to structurally expand operating margins back toward historical peaks.
The rapid adoption of GLP-1 therapies poses a long-term risk to legacy caloric volumes, requiring adaptive product innovation in clinical nutrition.
Geopolitical disruptions and climate volatility introduce persistent input cost inflation across agricultural and packaging supply chains, squeezing gross margins.
High free cash flow conversion provides substantial downside protection and supports ongoing capital return programs in a restrictive monetary environment.
Divergent views persist regarding whether current volume stagnation represents a cyclical trough or a terminal structural decline of the brand moat.
Portfolio optimization through strategic divestitures of lower-margin segments is expected to improve overall return on invested capital and streamline operations.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Nestlé quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in CHF; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Nestlé.
Quarter	Forecast date	Bear Case (CHF)	Base Case (CHF)	Bull Case (CHF)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 03, 2026	81.17 CHF	86.03 CHF	87.93 CHF	$736.09
Quarter 2+6M	Jan 03, 2027	78.73 CHF	87.07 CHF	92.33 CHF	$724.14
Quarter 3+9M	Apr 03, 2027	77.16 CHF	89.55 CHF	95.10 CHF	$713.57
Quarter 4+1Y	Jul 03, 2027	78.74 CHF	91.26 CHF	97.02 CHF	$723.38
Quarter 5+15M	Oct 03, 2027	77.17 CHF	91.93 CHF	100.90 CHF	$716.61
Quarter 6+18M	Jan 03, 2028	74.08 CHF	94.16 CHF	103.93 CHF	$738.34
Quarter 7+21M	Apr 03, 2028	74.08 CHF	95.77 CHF	106.00 CHF	$746.91
Quarter 8+2Y	Jul 03, 2028	72.60 CHF	97.79 CHF	109.18 CHF	$771.93
Quarter 9+27M	Oct 03, 2028	74.78 CHF	98.79 CHF	111.37 CHF	$782.73
Quarter 10+30M	Jan 03, 2029	75.51 CHF	99.83 CHF	114.71 CHF	$807.31
Quarter 11+33M	Apr 03, 2029	75.51 CHF	101.58 CHF	117.00 CHF	$822.72
Quarter 12+3Y	Jul 03, 2029	75.51 CHF	103.44 CHF	120.51 CHF	$846.10
Quarter 13+39M	Oct 03, 2029	74.00 CHF	104.82 CHF	122.92 CHF	$852.53
Quarter 14+42M	Jan 03, 2030	73.26 CHF	106.94 CHF	126.61 CHF	$882.91
Quarter 15+45M	Apr 03, 2030	71.79 CHF	107.53 CHF	129.14 CHF	$900.46
Quarter 16+4Y	Jul 03, 2030	72.51 CHF	109.07 CHF	131.73 CHF	$922.67
Quarter 17+51M	Oct 03, 2030	71.79 CHF	110.40 CHF	134.36 CHF	$935.91
Quarter 18+54M	Jan 03, 2031	70.35 CHF	112.54 CHF	138.39 CHF	$952.30
Quarter 19+57M	Apr 03, 2031	69.65 CHF	113.80 CHF	141.16 CHF	$976.28
Quarter 20+5Y	Jul 03, 2031	71.04 CHF	116.19 CHF	143.98 CHF	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's failure to recognize the structural margin expansion coiling beneath temporary operational noise. While the crowd focuses on near-term volume stagnation and treats weight-loss drugs as an existential threat, they overlook the company's aggressive cost-extraction initiatives and its rapid adaptation into clinical companion nutrition. The market is pricing the asset at a historically depressed valuation multiple, assuming permanent impairment. However, the company's pricing power remains highly resilient, and its strategic pivot toward high-margin categories like pet care and specialized health science is set to drive significant return on invested capital. This creates a major asymmetry between the current distressed price and the long-term durability of its cash-generation engine.

Advisor Disagreement

The primary disagreement across reports centers on the long-term impact of metabolic weight-loss drugs on the company's terminal value. Some perspectives model a structural, irreversible decline in caloric demand, viewing the company as a legacy incumbent trapped in a dying paradigm. Conversely, other reports argue that the threat is cyclically overstated and that the company's rapid pivot into clinical nutrition and high-margin companion products will successfully offset volume declines. Additionally, there is disagreement regarding the timeline for margin recovery, with opinions split on how quickly cost-cutting initiatives can neutralize persistent supply-chain inflation.

Financial Reviews by iPulse AI

Earnings and financials

Recent financial trends show a slight drop in overall revenue and net income, mostly because the company has faced slow sales volumes and tough foreign exchange rates. However, the business continues to generate an incredibly strong and steady flow of cash. Reports agree that the core cash-making engine is completely healthy, but they disagree on what the future holds. Some experts believe that the company's plan to cut jobs and sell off weaker divisions will quickly boost profits and lead to strong earnings growth. Others worry that as long as weight-loss drugs and high inflation persist, the company will struggle to sell more actual products, making its future earnings fragile. Overall, while the business is currently in a slow patch, its massive cash generation provides a strong safety net for investors.

Profitability and margins

Profit margins have faced some pressure recently due to rising costs for shipping, packaging, and raw ingredients like cocoa and coffee. To protect its profits, the company has aggressively raised prices, but this has made some consumers trade down to cheaper store brands. Reports agree that the company's pricing power has helped keep gross margins relatively stable, but they clash on the future outlook. Optimistic views argue that as raw material costs normalize and cost-cutting plans take effect, profit margins will expand significantly. Cautious views warn that price hikes have hit a wall, and if sales volumes continue to drop, the company will face severe margin pressure that cost-cutting cannot fix. For now, margins are holding up, but the battle between raising prices and keeping customers is key.

Balance sheet and leverage

The company's balance sheet is widely seen as a financial fortress, offering excellent safety during economic storms. Although its debt levels have risen over the past few years due to past stock buybacks and dividend payments, its ability to pay off its interest remains exceptionally strong. Reports agree that the company's massive cash generation virtually eliminates any risk of financial distress. However, there is a clear disagreement on how this debt affects the company's future. Some views suggest that the heavy debt load acts as a straitjacket, limiting the company's ability to buy new businesses or buy back its own shares. Others argue that the balance sheet is highly optimized and that upcoming cash from selling off weaker divisions will easily allow the company to pay down debt and reward shareholders.

Capex and investment intensity

The company keeps its capital spending very disciplined, usually spending a steady five to six percent of its revenue on maintaining and upgrading its business. This low spending level is great for protecting cash flow, especially when borrowing money is expensive. Reports agree that the company is shifting its investment strategy away from heavy, low-return physical factories and toward smart technology, automation, and high-growth areas like specialized nutrition and pet care. However, there is some disagreement about whether this defensive spending is enough. Some analysts believe this disciplined approach is perfect for a mature company, while others argue that the business needs to spend much more aggressively on advanced food science and biotechnology to survive major shifts in how people eat.